Agios Pharmaceuticals Inc
General ticker "AGIO" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $2.8B
Agios Pharmaceuticals Inc follows the US Stock Market performance with the rate: 60.9%.
Estimated limits based on current volatility of 5.3%: low 34.24$, high 38.05$
Factors to consider:
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [18.69$, 36.09$]
- 2024-12-30 to 2025-12-30 estimated range: [16.35$, 32.24$]
Financial Metrics affecting the AGIO estimates:
- Negative: Non-GAAP EPS, $ of -6.34 <= 0.10
- Negative: Operating profit margin, % of -93.59 <= 1.03
- Negative: Operating cash flow per share per price, % of -18.96 <= 2.35
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -26.04 <= 1.31
- Negative: -0.39 < Industry inventory ratio change (median), % of 0
Short-term AGIO quotes
Long-term AGIO plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $14.24MM | $26.82MM |
| Operating Expenses | $378.42MM | $403.29MM | $418.31MM |
| Operating Income | $-378.42MM | $-389.05MM | $-391.49MM |
| Non-Operating Income | $21.91MM | $157.25MM | $39.40MM |
| Interest Expense | $0.00MM | $12.79MM | $0.00MM |
| R&D Expense | $256.97MM | $279.91MM | $288.90MM |
| Income(Loss) | $-356.51MM | $-231.80MM | $-352.09MM |
| Other Income(Loss) | $1,961.22MM | $0.00MM | $0.00MM |
| Profit(Loss) | $1,604.71MM | $-231.80MM | $-352.09MM |
| Stockholders Equity | $1,291.97MM | $1,100.81MM | $811.02MM |
| Inventory | $16.19MM | $8.49MM | $19.08MM |
| Assets | $1,437.74MM | $1,238.72MM | $937.12MM |
| Operating Cash Flow | $-407.32MM | $-309.48MM | $-296.06MM |
| Capital expenditure | $5.74MM | $4.88MM | $1.00MM |
| Investing Cash Flow | $1,248.78MM | $243.26MM | $239.57MM |
| Financing Cash Flow | $-765.77MM | $2.35MM | $5.43MM |
| Earnings Per Share* | $26.55 | $-1.36 | $-6.33 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.